Plexision develops cellular biomarkers for personalized diagnosis and drug development in solid organ transplantation, and immunological disorders.
Plexision's first patented product, the PleximmuneTM assay, predicts the risk of transplant rejection. The test is based on patent-pending technology to measure antigen-specific white blood cells.
Testing services for transplant recipients and drug developers are provided at Plexision’s CLIA-certified, central laboratory in Pittsburgh.
Plexision currently offers cell-based testing for personalized assessment of rejection risk after solid organ transplantation The Pleximmune blood test is the first such test offered for children with liver or intestine transplantation.
Company Details
- Employees
- 10
- Founded
- -
- Address
- 4424 Penn Ave,
- Phone
- +1 (855) 753-9474
- in****@****ion.com
- Industry
- Biotechnology
- Website
- plexision.com
- HQ
- Pittsburgh, Pennsylvania
Plexision Questions
Plexision's helpline number is +1 (855) 753-9474
Plexision's website is plexision.com
Plexision's LinkedIn profile is https://www.linkedin.com/company/plexision
Plexision has
10 employees.
View email and phone details for 10
employees at Plexision.
Plexision's industry is
Biotechnology
Plexision's top competitors are
Digi-Prex,
Kidney Research Institute,
Good Health Company,
Antler Technologies,
Rockford Group Investment Advisor,
Grant Thornton (Us),
Peca Labs,
Sanofi,
Advanced Cardiopulmonary Solutions, Llc,
Castle Biosciences, Inc..
Plexision's support email address is info@plexision.com
Plexision's categories are Biotechnology
Plexision's founding year is 2008
